Zonisamide (Zonegran)

Zonisamide, marketed under the brand name Zonegran, is a sulfonamide anticonvulsant medication that has become an increasingly important option for managing seizures in dogs with epilepsy. Originally developed for human use and approved by the FDA for treating partial seizures in adults, zonisamide has found significant application in veterinary medicine as both a primary anticonvulsant and an add-on therapy for dogs whose seizures are not adequately controlled with other medications. The drug offers a combination of efficacy and tolerability that makes it valuable for many canine patients, particularly those who have not responded well to or cannot tolerate traditional first-line anticonvulsants like phenobarbital.

Zonisamide works through multiple mechanisms of action that contribute to its anticonvulsant effects, making it a broad-spectrum seizure medication capable of addressing various seizure types. The drug blocks voltage-gated sodium channels, reducing the rapid firing of neurons that characterizes seizure activity. Additionally, zonisamide blocks T-type calcium channels and weakly inhibits the enzyme carbonic anhydrase. It also appears to modulate GABAergic and glutamatergic neurotransmission, further contributing to seizure suppression. This multifaceted mechanism may explain why zonisamide can be effective in some dogs who have not responded to medications with single mechanisms of action, making it a valuable option for refractory epilepsy.

Zonisamide is available as oral capsules in various strengths, allowing for flexible dosing across the range of dog sizes encountered in veterinary practice. The capsules can be opened and the contents mixed with food for dogs who have difficulty swallowing pills, though the contents should not be chewed due to their bitter taste. Generic zonisamide has become available, improving affordability compared to when only the brand-name Zonegran was available. The drug is typically administered twice daily in dogs due to its pharmacokinetic profile in this species, though individual patients may have their dosing schedule adjusted based on response and tolerability.

The safety profile of zonisamide in dogs is generally favorable, though it does require attention to certain monitoring parameters. Unlike phenobarbital, zonisamide does not cause the hepatic enzyme induction that leads to the complex drug interactions and potential liver toxicity associated with that older medication. However, zonisamide does undergo hepatic metabolism and has been associated with hepatotoxicity in some patients, necessitating periodic liver function monitoring. The drug's status as a sulfonamide derivative means that dogs with known sulfa allergies should not receive it. Overall, zonisamide provides veterinarians with another effective tool for managing canine epilepsy, particularly valuable as an alternative or addition to traditional anticonvulsants.

The primary indication for zonisamide in veterinary medicine is the management of seizures in dogs with idiopathic epilepsy, where it may be used as either a first-line therapy or as an adjunctive medication in combination with other anticonvulsants. Idiopathic epilepsy, the most common cause of recurrent seizures in dogs, typically requires lifelong medication management, and zonisamide has proven effective in reducing seizure frequency in many affected patients. The drug's multiple mechanisms of action allow it to address various seizure types, including generalized tonic-clonic seizures and focal seizures, making it a versatile choice for canine epilepsy management.

Refractory epilepsy represents a particularly important indication for zonisamide use in dogs. Dogs whose seizures persist despite appropriate therapy with first-line anticonvulsants such as phenobarbital or potassium bromide may benefit from the addition of zonisamide to their treatment protocol. The different mechanism of action compared to traditional anticonvulsants allows zonisamide to provide additional seizure suppression through pathways not addressed by the existing medication regimen. Many veterinary neurologists consider zonisamide a preferred option for add-on therapy when dogs require intensification of their anticonvulsant treatment, and studies have shown meaningful reduction in seizure frequency when zonisamide is added to existing therapy.

Zonisamide is sometimes selected as a first-line anticonvulsant for dogs in situations where phenobarbital is not appropriate. Dogs with pre-existing liver disease or those belonging to breeds predisposed to hepatic problems may be better candidates for zonisamide, which has less impact on liver enzymes than phenobarbital. The lack of controlled substance regulations surrounding zonisamide simplifies prescription and dispensing compared to phenobarbital and may be preferred by some owners. Dogs who experience unacceptable sedation or other side effects from phenobarbital might tolerate zonisamide better, as its side effect profile differs from that of barbiturate medications.

Beyond idiopathic epilepsy, zonisamide may be prescribed for seizure control in dogs with symptomatic epilepsy secondary to identified brain pathology, including structural lesions, inflammatory conditions, or metabolic disturbances. While addressing the underlying cause remains the primary goal in these cases, zonisamide provides symptomatic seizure control during diagnosis and treatment of the primary condition. Dogs recovering from brain surgery or other neurological procedures may receive anticonvulsant therapy to reduce the risk of post-procedural seizures, and zonisamide is among the options available for this purpose.

When selecting zonisamide for canine patients, veterinarians consider multiple factors including the specific seizure characteristics, the dog's overall health status, concurrent medications, owner preferences, and practical considerations. The drug may be chosen when liver concerns make phenobarbital less desirable, when dogs have not responded adequately to other anticonvulsants, or when the owner prefers a medication without controlled substance requirements. The twice-daily dosing schedule is manageable for most owners, though it does require more frequent administration than once-daily options. Cost considerations have improved with the availability of generic zonisamide, though the medication remains more expensive than phenobarbital in many cases.

Zonisamide dosing in dogs requires careful veterinary calculation and individualization based on the patient's weight, seizure characteristics, concurrent medications, and response to therapy. The veterinarian determines appropriate doses through assessment of the individual patient and may adjust dosing based on seizure control and tolerability. As with all anticonvulsants, owners should not modify zonisamide doses without veterinary guidance, as improper dosing can result in breakthrough seizures or increased side effects. Accurate weight measurement is essential for proper dose calculation, and significant weight changes should be communicated to the veterinarian so that doses can be recalculated as needed.

Typical starting doses of zonisamide for dogs range from 5 to 10 milligrams per kilogram of body weight daily, usually divided into two doses given approximately twelve hours apart. The twice-daily dosing schedule maintains more stable blood levels than once-daily administration and is standard for most patients. Some veterinarians start at the lower end of the dosing range and increase gradually based on seizure response, while others may begin with higher doses if seizure activity is frequent or severe. Unlike phenobarbital, routine therapeutic drug monitoring of zonisamide blood levels is not universally recommended, though measuring levels may be helpful in dogs who are not responding as expected or who experience side effects at typical doses.

When zonisamide is added to an existing anticonvulsant regimen, interactions with other medications must be considered. Dogs receiving phenobarbital will metabolize zonisamide more rapidly due to phenobarbital's induction of hepatic enzymes, potentially requiring higher zonisamide doses to achieve adequate blood levels. Conversely, dogs receiving zonisamide as a sole therapy may achieve therapeutic effects at lower doses. The veterinarian adjusts dosing based on clinical response, with the goal of achieving optimal seizure control with minimal side effects. Dogs typically require two to three weeks of consistent dosing before steady-state blood levels are achieved and the full effect of a dose change can be assessed.

Zonisamide capsules can be given with or without food, though some dogs may experience less gastrointestinal upset when the medication is administered with a meal. For dogs who cannot swallow capsules whole, the capsules may be opened and the contents mixed with a small amount of palatable food. However, the powder has a bitter taste, so mixing with strongly flavored food or a small treat may improve acceptance. The contents should not be chewed, as this releases the bitter taste more prominently. Maintaining consistent timing between doses helps achieve stable blood levels and optimal seizure control, and owners should establish a regular medication schedule integrated into their daily routine.

If a dose of zonisamide is missed, it should be given as soon as remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped and the regular schedule resumed. Double doses should never be given to make up for missed doses. Occasional single missed doses in dogs with well-controlled epilepsy are unlikely to immediately trigger breakthrough seizures, but consistent daily administration is important for maintaining therapeutic benefit. If multiple doses are missed, owners should contact their veterinarian for guidance on safely resuming therapy.

Zonisamide therapy should not be discontinued abruptly in dogs receiving it for seizure control, as sudden withdrawal of any anticonvulsant can potentially trigger breakthrough seizures. If discontinuation is desired, the veterinarian will provide guidance on gradually tapering the dose over an appropriate time period. Even with careful tapering, some dogs may experience increased seizure activity if zonisamide is withdrawn, reflecting the ongoing nature of the underlying epilepsy rather than a withdrawal effect. Any changes to the anticonvulsant regimen should be made under veterinary supervision with appropriate monitoring for changes in seizure control.

Zonisamide is generally well-tolerated by most dogs, with side effects typically being mild and often improving as the patient adjusts to the medication. The side effect profile of zonisamide differs from that of phenobarbital and other traditional anticonvulsants, which may make it preferable for dogs who experienced problematic effects from those medications. Understanding potential side effects allows owners to monitor their dogs appropriately and communicate observations to their veterinarian. Most side effects are dose-related and may improve with dose reduction if they become troublesome while still maintaining seizure control.

The most commonly observed side effects of zonisamide in dogs include sedation, decreased appetite, and ataxia, or unsteady gait. These effects are typically most pronounced during the first few weeks of therapy and often diminish as the dog develops tolerance. The sedative effect of zonisamide is generally less pronounced than that of phenobarbital, making it attractive for dogs where excessive sedation significantly impacts quality of life. Some dogs experience gastrointestinal effects including vomiting, diarrhea, or changes in stool consistency, particularly when starting therapy or after dose increases. These effects are usually transient and may be reduced by giving the medication with food.

Behavioral changes have been reported in some dogs receiving zonisamide, including agitation, restlessness, or changes in demeanor that owners may describe as the dog seeming different from their usual self. These effects are variable and may resolve with continued therapy or dose adjustment. Incoordination or wobbliness may occur, particularly at higher doses, and should be monitored to ensure the dog can safely navigate their environment without risk of falls or injury. Some dogs experience changes in urination patterns, including increased or decreased frequency, which may be related to zonisamide's weak carbonic anhydrase inhibition affecting kidney function.

Moderate side effects warranting veterinary attention include persistent gastrointestinal upset affecting appetite or nutritional status, significant behavioral changes impacting quality of life, or sedation that prevents normal activities even after a reasonable adjustment period. Zonisamide has been associated with hepatotoxicity in dogs, making liver function monitoring important during therapy. Signs of liver problems such as jaundice, persistent vomiting, loss of appetite, or changes in behavior should prompt veterinary evaluation. Because zonisamide is a sulfonamide derivative, dogs with sulfa sensitivities should not receive it, and any signs of allergic reaction such as skin rash, facial swelling, or difficulty breathing require immediate attention.

Serious side effects with zonisamide are uncommon but important to recognize. Severe hepatotoxicity, while rare, can be life-threatening and requires prompt intervention. Keratoconjunctivitis sicca, or dry eye, has been reported as an idiosyncratic reaction in dogs receiving zonisamide and may present as eye redness, discharge, or squinting. Kidney stones or urinary tract effects are possible given zonisamide's carbonic anhydrase inhibition. Blood cell abnormalities have been reported rarely. Severe allergic reactions, though uncommon, can occur with any medication. Any new or concerning symptoms during zonisamide therapy should be reported to the veterinarian for evaluation. The overall safety profile of zonisamide remains favorable for most dogs, but appropriate monitoring helps ensure early detection of any adverse effects.

Zonisamide should not be administered to dogs with known hypersensitivity to sulfonamide medications, as the drug is a sulfonamide derivative and cross-reactivity can occur. Dogs who have experienced allergic reactions to sulfa antibiotics or other sulfonamide-containing medications face increased risk of allergic reactions to zonisamide. Signs of sulfonamide allergy can include skin rashes, hives, facial swelling, difficulty breathing, or fever. Owners should inform their veterinarian of any known drug allergies, particularly to sulfa-containing medications, before starting zonisamide therapy. If the dog's medication allergy history is uncertain, careful monitoring during initial therapy is warranted.

Significant liver disease represents an important contraindication for zonisamide use due to the drug's hepatic metabolism and potential for hepatotoxicity. Dogs with pre-existing hepatic dysfunction, elevated liver enzymes, or history of liver disease may be at increased risk for drug-induced liver damage when receiving zonisamide. Alternative anticonvulsants that do not require hepatic metabolism, such as levetiracetam or potassium bromide, may be more appropriate for dogs with significant liver concerns. If zonisamide is deemed necessary for a dog with mild hepatic compromise, very careful monitoring with frequent liver function testing is essential. Any signs of liver problems during therapy should prompt immediate veterinary evaluation and potentially discontinuation of the medication.

Kidney disease warrants consideration when prescribing zonisamide, as the drug and its metabolites are eliminated through the kidneys. Additionally, zonisamide's carbonic anhydrase inhibition can affect kidney function and potentially contribute to kidney stone formation in susceptible individuals. Dogs with severe renal impairment may require dose adjustments or alternative anticonvulsant selection. Regular monitoring of kidney function is appropriate for dogs on long-term zonisamide therapy, particularly those with any pre-existing renal concerns. Maintaining adequate hydration is important for all dogs receiving zonisamide to support kidney function and reduce stone risk.

Pregnancy and lactation require careful consideration with zonisamide, as with most anticonvulsant medications. The effects of zonisamide on fetal development in dogs have not been thoroughly studied, and potential risks exist based on data from other species and the drug's mechanism of action. Zonisamide should be used in pregnant dogs only when the benefits of seizure control clearly outweigh potential risks to developing puppies. The drug likely passes into breast milk, potentially affecting nursing puppies. Veterinarians carefully weigh these factors when treating pregnant or lactating dogs with epilepsy. Very young puppies may be more sensitive to medication effects due to developing organ systems and should be treated with caution. Complete disclosure of reproductive status and all health conditions ensures the veterinarian can make appropriate treatment recommendations.

Informing your veterinarian about all medications, supplements, and treatments your dog receives is essential before starting zonisamide therapy and throughout treatment. While zonisamide has fewer drug interactions than phenobarbital, several important interactions can affect its efficacy and safety. Understanding these interactions helps veterinarians design optimal treatment protocols and ensures that owners can monitor for signs of interaction effects. Maintaining a comprehensive medication list and sharing it with all veterinary providers ensures complete awareness of potential concerns.

The most clinically significant interaction involving zonisamide occurs when it is used in combination with phenobarbital, a common scenario in dogs with refractory epilepsy requiring multiple anticonvulsants. Phenobarbital induces hepatic enzymes that accelerate the metabolism of zonisamide, resulting in lower zonisamide blood levels than would be achieved in dogs receiving zonisamide alone. This interaction means that dogs on concurrent phenobarbital therapy often require higher zonisamide doses to achieve adequate seizure control. The half-life of zonisamide is significantly shortened in dogs receiving phenobarbital, which may also affect the dosing interval. Veterinarians account for this interaction when prescribing combination therapy and may use blood level monitoring to guide dose optimization.

Other enzyme-inducing medications can similarly affect zonisamide metabolism, though these interactions are less commonly encountered in veterinary practice. Any medication that increases hepatic enzyme activity could potentially reduce zonisamide effectiveness by accelerating its clearance. Conversely, drugs that inhibit hepatic enzymes could increase zonisamide blood levels and the risk of side effects. The veterinarian considers potential interactions when adding any new medication to the regimen of a dog receiving zonisamide and may recommend monitoring for changes in seizure control or side effect development.

Additive central nervous system depression may occur when zonisamide is combined with other sedating medications, including other anticonvulsants, opioid pain medications, antihistamines, or anti-anxiety drugs. While this interaction is typically manageable, owners should be aware of the potential for increased sedation when multiple such medications are used together. The carbonic anhydrase inhibition caused by zonisamide could theoretically interact with other medications affecting acid-base balance or kidney function, though this is rarely a clinical concern at typical anticonvulsant doses. Supplements and herbal products with sedating properties may add to zonisamide's central nervous system effects and should be disclosed to the veterinarian.

Monitoring for drug interactions involves observing for changes in seizure control, unexpected side effects, or alterations in the effects of other medications. When zonisamide is added to an existing phenobarbital regimen, the veterinarian may check zonisamide blood levels after steady state is reached to ensure adequate dosing. Any significant changes in the dog's response to medications, seizure pattern, or overall condition should be reported promptly. The relatively limited interaction profile of zonisamide compared to phenobarbital makes it a useful option for dogs requiring multiple medications, though careful attention to known interactions remains important for optimizing therapy.

Careful attention to monitoring and adherence to veterinary instructions is essential for safe and effective zonisamide therapy in dogs. While zonisamide does not require the intensive blood level monitoring associated with phenobarbital, periodic assessment of liver and kidney function is recommended during long-term therapy. These monitoring tests help detect any adverse organ effects before they become clinically significant and provide reassurance that the medication continues to be safe for the individual patient. The veterinarian will recommend an appropriate monitoring schedule based on the dog's overall health status and duration of therapy.

Owners should be aware of the signs of potential hepatotoxicity and report any concerning symptoms promptly. Early signs of liver problems may include decreased appetite, lethargy, vomiting, or jaundice, which appears as yellowing of the whites of the eyes, gums, or skin. Any such symptoms during zonisamide therapy warrant immediate veterinary evaluation and potentially liver function testing. While hepatotoxicity with zonisamide is uncommon, awareness and prompt recognition can prevent serious outcomes. Baseline liver function assessment before starting therapy provides a reference point for future monitoring and helps identify dogs who may be at higher risk for hepatic effects.

Breed-specific considerations with zonisamide are less pronounced than with some other anticonvulsants, as the drug's metabolism and handling do not appear to vary dramatically between breeds. The MDR1 gene mutation common in herding breeds does not significantly affect zonisamide, making it a reasonable choice for breeds where this mutation is prevalent. However, individual variation exists within any breed, and some dogs may be more sensitive to medication effects than others. Breeds predisposed to liver disease may warrant more careful monitoring during zonisamide therapy. Giant breeds require appropriate dose calculations, while toy breeds need precise dosing to avoid inadvertent over- or underdosing.

Special populations requiring additional consideration include dogs with kidney disease, who may have altered zonisamide elimination and increased risk of urinary complications. Maintaining adequate hydration is particularly important for these patients. Senior dogs may have age-related declines in organ function that affect drug handling, and more frequent monitoring may be appropriate. Puppies have developing organ systems that may respond differently to medications. Dogs with conditions affecting the eyes should have baseline ophthalmic evaluation, as keratoconjunctivitis sicca has been reported as a rare side effect of zonisamide. Working dogs and service dogs should be monitored for any effects that might impact their function.

Maintaining a seizure diary is recommended for all dogs receiving anticonvulsant therapy, including those on zonisamide. Recording seizure dates, times, duration, and characteristics helps assess treatment effectiveness and guides dosing decisions. Notes about potential triggers, medication administration, and any observed side effects provide valuable context for veterinary consultations. Any significant changes in seizure pattern or frequency should be communicated to the veterinarian promptly. Regular follow-up appointments allow for assessment of treatment response and adjustment of therapy as needed to maintain optimal seizure control while minimizing adverse effects.

Proper storage of zonisamide helps maintain the medication's effectiveness and ensures household safety. Zonisamide capsules and tablets should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, in a dry location protected from moisture and light. Bathroom storage is not recommended due to humidity from showers and bathing. The medication should remain in its original container, which provides appropriate protection and contains important information about the product. Excessive heat, direct sunlight, and freezing temperatures should be avoided, as extreme conditions can degrade medication potency. Checking expiration dates periodically ensures that medication will be effective when administered.

The non-controlled status of zonisamide means that storage requirements are less stringent than for medications like phenobarbital, but safe storage remains important for household safety. The medication should be kept in a location inaccessible to children, as accidental ingestion could cause significant effects including sedation and gastrointestinal upset. Other pets in the household should similarly be unable to access zonisamide, even though the bitter taste of the capsule contents makes them unappealing to most animals. Child-resistant containers should be properly closed after each use, and medication should never be left loose or in easy-open containers around curious children or pets.

Zonisamide capsules should be kept dry and handled with dry hands to prevent moisture degradation. If capsules are opened to mix contents with food, this should be done immediately before administration rather than in advance, as exposure to air and moisture can affect the medication. Any capsules that appear damaged, discolored, or altered from their normal appearance should not be used. The bitter taste of zonisamide powder means that dogs may reject food containing the medication if too much is used or if the powder is not adequately disguised. Using strongly flavored foods or small amounts of palatable treats typically improves acceptance.

Proper disposal of unused or expired zonisamide should follow standard medication disposal guidelines. While not a controlled substance, medications should not be kept indefinitely or discarded in household trash where they might be accessible to children, pets, or wildlife. Many pharmacies and veterinary clinics accept unused medications for proper disposal. Community drug take-back programs provide another option for safe medication disposal. If no take-back options are available, the FDA recommends mixing unused medication with an undesirable substance like coffee grounds or cat litter, placing in a sealed container, and disposing in household trash. Flushing medications is generally not recommended due to environmental concerns. Empty prescription containers should have personal information removed before disposal.

Zonisamide demonstrates consistent effectiveness across the diverse range of canine breeds, making it a versatile option for seizure management regardless of breed-specific factors. The drug's metabolism and safety profile do not appear to vary dramatically between breeds, allowing veterinarians to prescribe it with confidence for patients of any breed type. Understanding general breed-related considerations helps optimize therapy while recognizing that individual patient assessment remains most important for treatment planning. Most dogs can be successfully managed with zonisamide when appropriate monitoring is maintained.

The MDR1 gene mutation, which significantly affects the handling of many medications in herding breeds, does not substantially impact zonisamide therapy. Dogs with this mutation, including Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, German Shepherds, and related breeds, can generally receive standard zonisamide doses without concerns related to the mutation. This makes zonisamide a viable option for herding breed dogs who may need to avoid other medications due to MDR1 considerations. Genetic testing for MDR1 status remains valuable for overall medication planning but does not typically change zonisamide prescribing decisions.

Liver function considerations may be relevant for certain breeds when planning zonisamide therapy, as the drug undergoes hepatic metabolism and has been associated with hepatotoxicity. Breeds with increased predisposition to liver disease, including certain terrier breeds, Doberman Pinschers, and others, may warrant baseline liver function assessment and potentially more frequent monitoring during therapy. This consideration applies to many anticonvulsants, and zonisamide is not necessarily more concerning than alternatives in this regard. Individual patient assessment, including pre-treatment liver enzyme evaluation, helps identify dogs who may be at higher risk and guides monitoring intensity.

Size considerations affect practical aspects of zonisamide therapy across breeds. Giant breeds such as Great Danes, Irish Wolfhounds, Mastiffs, and Saint Bernards require appropriate dose calculations that may result in multiple capsules per dose. The availability of different capsule strengths helps accommodate larger dogs. Toy breeds including Chihuahuas, Yorkshire Terriers, and similar small dogs require precise dosing where small errors have proportionally larger effects. Opening capsules and mixing the contents with food allows for more flexible dosing for very small dogs, though care must be taken to ensure the complete dose is consumed. Accurate and current weight measurement is essential for all sizes.

Age-related factors intersect with breed in determining appropriate zonisamide protocols. Giant breeds have shorter lifespans and reach geriatric status earlier than small breeds, potentially affecting organ function and drug handling at younger chronological ages. Senior dogs of any breed may have age-related declines in liver or kidney function that warrant dose adjustments or more frequent monitoring. Certain breeds have recognized increased prevalence of idiopathic epilepsy, including Beagles, Belgian Tervurens, German Shepherds, Golden Retrievers, and Labrador Retrievers among others, making anticonvulsant therapy a common need in these populations. Understanding breed-specific seizure patterns helps veterinarians set appropriate treatment expectations.

Several other anticonvulsant medications serve as alternatives or complements to zonisamide in canine epilepsy management, providing options tailored to individual patient needs and circumstances. Phenobarbital remains one of the most commonly prescribed anticonvulsants for dogs due to its proven efficacy, extensive clinical experience, and low cost. However, phenobarbital requires routine blood monitoring for drug levels and liver function and is associated with hepatic enzyme induction that can affect other medications. For dogs who cannot tolerate phenobarbital or who have liver concerns, zonisamide provides an alternative with a different mechanism of action and side effect profile.

Potassium bromide offers another traditional option for canine epilepsy management, either as monotherapy or in combination with other anticonvulsants. Unlike zonisamide and phenobarbital, potassium bromide does not undergo hepatic metabolism, making it suitable for dogs with liver disease. However, potassium bromide has a very long half-life requiring weeks to months to reach steady state, and it has its own considerations including potential for bromide toxicity and dietary chloride interactions. Dogs with kidney disease may not be suitable candidates for potassium bromide therapy.

Levetiracetam has become increasingly popular in veterinary neurology due to its excellent safety profile, minimal drug interactions, and lack of required routine blood monitoring. It represents another option for dogs who cannot receive phenobarbital and may be preferred over zonisamide in some situations due to its more predictable pharmacokinetics and lower risk of hepatotoxicity. However, levetiracetam typically requires more frequent dosing than zonisamide and may be more expensive. Gabapentin, while primarily used for pain management, has anticonvulsant properties and may be included in combination protocols for refractory epilepsy.

Complementary approaches may support seizure management alongside appropriate anticonvulsant medications. Dietary modifications, including medium-chain triglyceride supplementation, have shown promise for improving seizure control in some dogs. Maintaining consistent routines, ensuring adequate rest, reducing stress, and identifying potential seizure triggers may help reduce seizure frequency. Regular veterinary follow-up allows for ongoing assessment and optimization of treatment. Owners should never adjust anticonvulsant doses or discontinue medications without veterinary guidance, as doing so can result in breakthrough seizures or status epilepticus. All treatment decisions, including the addition of supplements or dietary changes, should be made in consultation with a veterinarian experienced in epilepsy management to ensure the safest and most effective approach for each individual patient.